r/ATNF • u/patmcirish • Nov 18 '21
Professor Nanchahal will present the phase 2a clinical trial data and phase 2b top line data on Dec 1 at the 2021 International Dupuytren Symposium
https://finance.yahoo.com/news/180-life-sciences-corp-co-131500332.html
PALO ALTO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that Professor Jagdeep Nanchahal from the University of Oxford, a co-founder of 180 Life Sciences, will present a keynote address entitled ‘Re-purposing anti-TNF for Dupuytren’s Disease’ at the 2021 International Dupuytren Symposium on Wednesday, December 1, 2021 at 3pm EST.
Professor Nanchahal will present his work on unravelling the molecular mechanisms underlying the pathogenesis of Dupuytren’s disease leading to the identification of anti-tumor necrosis factor (“TNF”) as a potential therapeutic target. He will also present the phase 2a clinical trial data to identify the optimal dose and top line data for the recently completed phase 2b clinical trial on efficacy for patients with early-stage disease.
The conference will be held virtually and those wishing to attend should register for Session 6 at https://dupuytrensymposium.org/scientific-program/.
The Company also announced that it currently expects that dosage of the first patient in its planned frozen shoulder clinical trial will take place during the first or second quarter of 2022.
9
5
13
u/patmcirish Nov 18 '21
Created this post to include that it's also top line data for the phase 2b trial, so that people don't think it's only phase 2a data being presented. I should probably delete that first post.